Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

a rodent model;

-- Silencing of KSP mRNA in vivo by greater than 50 percent after a single injection of a KSP-specific siRNA in a rodent model; and

-- Halting of human cancer cell proliferation in vitro when KSP was silenced by a target-specific siRNA.

Alnylam's RNAi therapeutic, ALN-VSP01, is comprised of two small interfering RNAs, or siRNAs, the molecules that mediate RNAi. Each siRNA targets a distinct and well-validated gene in the growth and proliferation of tumors: VEGF, a key mediator of tumor angiogenesis; and KSP, a protein required for cell division that, when inhibited, leads to cell arrest and cell death in dividing cells. ALN-VSP01 is formulated using Alnylam's novel liposomal formulation technology, which has been used to achieve delivery of siRNAs to cells of the liver and efficient silencing of genes expressed in that organ. Liposomal delivery can also be optimized for delivery to other organs and tumor types, such that ALN-VSP01 may ultimately have potential for a range of solid tumors. Alnylam's collaborator, Inex Pharmaceuticals Corporation, is manufacturing the lipid-based formulation as the company prepares for pre-IND toxicology studies with ALN-VSP01.

"Despite many advances in the treatment of cancer with targeted small molecules and antibody therapeutics, the clinical impact of these therapies is generally measured in only months of survival benefit. New modalities like RNAi therapeutics offer the potential to advance cancer therapy to a whole new level," said George D. Demetri, M.D., of Dana-Farber Cancer Institute and Harvard Medical School. "I'm encouraged by Alnylam's pre-clinical data demonstrating the ability to silence disease pathway genes with delivery of RNAi therapeutics, and believe that the application of this approach for the treatment of primary and secondary liver cancers holds considerable promise."

About Liver Cancer

Primary liver cancer is cancer that forms in the tissues of the l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Needles Market 2014-2018" report to their offering. ... hypodermic needle is a hollow needle commonly used with ... or to extract fluids from it. A hypodermic needle ... inject substances that cannot be ingested. Hypodermic needles are ...
(Date:7/11/2014)... , July 11, 2014 ... Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, ... Growth, Trends and Forecast, 2013-2019" the global endoscopy devices ... and is expected to grow at a CAGR of ... value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... -- Burn injuries increase in the summer as people gather ... Among those most vulnerable to these seasonal fire hazards: children. ... get burned by putting their hands on the side of ... unit at Loyola University Medical Center in Maywood, Ill., said ... ,When you play with fire, you get burned, is true ...
(Date:7/12/2014)... 12, 2014 “After my mom’s stroke, she loss ... stroke and loss the use of his left side. Eating became ... way to help people like them enjoy eating again,” said an ... for the PATRICIA CAROL HALL PLATE (P C H PLATE). , ... more ergonomic way to eat for individuals who suffer from stroke, ...
(Date:7/12/2014)... prom shopping reaching its final days, VogueQueen.com, a renowned ... its new and trendy apparels. Recently, the company has ... online shop. Additionally, it is now providing huge discounts ... to the company’s sales manager, the promotion will come ... He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... One way to respond to this is to blame the victimto ... another common response, according to a new study published in ... The researchers found that people who believe in justice in the ... meaning. "A lot of the time when people see ...
... (BUSM) have been awarded a five-year, $2 million grant ... Network (EDRN), as well as a four-year, $1.3 million ... will allow the scientists to develop novel and complementary ... patients. The grant from NCI will support ...
... in French . , MONTREAL, December 14, 2010 ... babies learn to recognize the sound of their parents, voice and ... between parents and newborns admitted to the intensive care unit can ... relationship. , Jan Lariviere, a nurse in the neonatal clinic and ...
... TUESDAY, Dec. 14 (HealthDay News) -- Prayer can help ... emotions by using coping methods such as venting, a ... people in abusive relationships who were interviewed by Shane ... Wisconsin, Madison. The racially diverse participants came from different ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Most of the ... is funded by states, not the federal government, a new ... the extent to which states prioritized human embryonic stem cell ... could likely have been funded under federal government guidelines established ...
... collaboration between researchers at the Salk Institute for Biological ... the tumor suppressor p53, long thought of as the ... cancer-causing mutations. It may also prevent established cancer cells ... serving as a "Guardian against Genome Reprogramming." The ...
Cached Medicine News:Health News:People who believe in justice also see a victim's life as more meaningful after tragedy 2Health News:Boston University School of Medicine awarded grants to improve early detection of lung cancer 2Health News:Once upon a time in the Intensive Care Unit ... 2Health News:Prayer May Help Victims of Domestic Abuse 2Health News:States Now Fund Most Embryonic Stem Cell Research in U.S. 2Health News:The stemness of cancer cells 2Health News:The stemness of cancer cells 3
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Integrity ADx pacemaker ... world's smallest dual-chamber pacemaker, ... pacemaker technology, including the ... the first U.S. commercially ...
... The Frontier II device ... symptoms of moderate to severe ... or IV) in patients who ... medical therapy and who have ...
Medicine Products: